Brivaracetam in the treatment of epilepsy: a review of clinical trial data

References

• Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385(9971):884–898. doi:10.1016/S0140-6736(14)60456-625260236
   PubMed Web of Science ®Google Scholar
• Schmidt D, Friedman D, Dichter MA. Anti-epileptogenic clinical trial designs in epilepsy: issues and options. Neurotherapeutics. 2014;11(2):401–411. doi:10.1007/s13311-013-0252-z24420312
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554. doi:10.1212/WNL.0b013e3182563b1922573629
   PubMed Web of Science ®Google Scholar
• Malek N, Heath CA, Greene J. A review of medication adherence in people with epilepsy. Acta Neurol Scand. 2017;135(5):507–515. doi:10.1111/ane.1270327781263
   PubMed Web of Science ®Google Scholar
• Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1–22. doi:10.2147/CPAA.S11407229403319
   PubMed Web of Science ®Google Scholar
• Willems LM, Bauer S, Rosenow F, Strzelczyk A. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Expert Opin Pharmacother. 2019;2:1–11. doi:10.1080/14656566.2019.1637420
   Web of Science ®Google Scholar
• Makke Y, Abou-Khalil B. Brivaracetam efficacy and safety in focal epilepsy. Expert Rev Neurother. 2019;24:1–10. doi:10.1080/14737175.2019.1631160
   Web of Science ®Google Scholar
• Hellerslia V, Asistido JM, Iyamu A. Brivaracetam for epilepsy. JAAPA. 2019;32(5):21–22. doi:10.1097/01.JAA.0000554748.77547.f8
   Google Scholar
• Ferlazzo E, Russo E, Mumoli L, et al. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015;11:2967–2973. doi:10.2147/NDT.S6084926664121
   PubMed Web of Science ®Google Scholar
• Coppola G, Iapadre G, Operto FF, Verrotti A. New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Des Devel Ther. 2017;11:643–657. doi:10.2147/DDDT.S103468
   PubMed Web of Science ®Google Scholar
• Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2019;3:CD011501. doi:10.1002/14651858.CD012521.pub230920649
   PubMed Web of Science ®Google Scholar
• Klitgaard H, Matagne A, Nicolas JM, et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57(4):538–548. doi:10.1111/epi.1334026920914
   PubMed Web of Science ®Google Scholar
• Margineanu D, Klitgaard H. The novel SV2A ligands brivaracetam and seletractam manifest different effects against the epileptiform markers of field potentials in a “high K + -low CA2 + ” rat hippocampal slice model. Annual Meeting of European Congress on Epileptology; 7 3; 2006; Helsinki, Finland.
   Google Scholar
• Stockis A, Hartstra J, Mollet M, Hadi S. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia. 2016;57(8):1288–1293. doi:10.1111/epi.1343327346728
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007;63(6):680–688. doi:10.1111/j.1365-2125.2006.02829.x17223857
   PubMed Web of Science ®Google Scholar
• Otoul C, Watanabe S, McCabe S, Stockis A. Relative bioavailability and bioequivalence of brivaracetam 10 mg/mL oral solution and 50-mg film-coated tablet. Clin Pharmacol Drug Dev. 2017;6(3):313–317. doi:10.1002/cpdd.27527274002
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–209. doi:10.1111/epi.1326726663401
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Espié P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36(1):36–45. doi:10.1124/dmd.107.01712917908923
   PubMed Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66(1):71–75. doi:10.1111/j.1365-2125.2008.03158.x18341673
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the tenth Eilat Conference (EILATX). Epilepsy Res. 2010;92(2–3):89–124. doi:10.1016/j.eplepsyres.2010.09.00120970964
   PubMed Web of Science ®Google Scholar
• Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol. 2013;53(6):633–641. doi:10.1002/jcph.8223649964
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Klein KM, Willems LM, Rosenow F, Bauer S. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016;9(5):637–645. doi:10.1586/17512433.2016.115652926891946
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis. Neurology. 2016;86(14):1344–1352. doi:10.1212/WNL.000000000000254526944275
   PubMed Web of Science ®Google Scholar
• Tiet MY, George J. Brivaracetam and levetiracetam dose adjustments leading to behavioural adverse effects. Postgrad Med J. 2017;93(1103):566. doi:10.1136/postgradmedj-2017-13481428596441
   PubMed Web of Science ®Google Scholar
• Swaine Z. Masked depression In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of Clinical Neuropsychology. New York: Springer; 2011:1524–1525.
   Google Scholar
• Stockis A, Chanteux H, Rosa M, Rolan P. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27. doi:10.1016/j.eplepsyres.2015.03.00325986188
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Fakhoury T, McDonough B, et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program. Epilepsy Res. 2018;145:55–62. doi:10.1016/j.eplepsyres.2018.06.00229908435
   PubMed Web of Science ®Google Scholar
• Otoul C, Von Rosentiel P, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures. Annual Meeting of American Epilepsy Society; 12 3; 2007; Philadelphia, PA. doi:10.1094/PDIS-91-4-0467B
   Google Scholar
• Stephen LJ, Brodie MJ. Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Ther Adv Neurol Disord. 2017; 11: 1756285617742081.29399049
   PubMed Web of Science ®Google Scholar
• Stockis A, Watanabe S, Scheen AJ, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos. 2016;44(6):792–799. doi:10.1124/dmd.115.06916127002062
   PubMed Web of Science ®Google Scholar
• Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia. 2014;55(3):e27–e31. doi:10.1111/epi.2014.55.issue-324512385
   PubMed Web of Science ®Google Scholar
• Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfán BV, Carmona-Aparicio L, Gómez-Lira G. Synaptic vesicle protein 2A: basic facts and role in synaptic function. Eur J Neurosci. 2013;38(11):3529–3539. doi:10.1111/ejn.1236024102679
   PubMed Web of Science ®Google Scholar
• Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A. 1999;96(26):15268–15273. doi:10.1073/pnas.96.26.1526810611374
   PubMed Web of Science ®Google Scholar
• van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia. 2009;50(3):422–433. doi:10.1111/j.1528-1167.2008.01727.x18717715
   PubMed Web of Science ®Google Scholar
• Wood MD, Sands ZA, Vandenplas C, Gillard M. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2018;59(9):e147–e151. doi:10.1111/epi.1453230144048
   PubMed Web of Science ®Google Scholar
• Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1–3):36–44. doi:10.1016/j.ejphar.2011.04.06421575627
   PubMed Web of Science ®Google Scholar
• Finnema SJ, Rossano S, Naganawa M, et al. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia. 2019;60(5):958–967. doi:10.1111/epi.1470130924924
   PubMed Web of Science ®Google Scholar
• Niespodziany I, Lukyanetz EA, Matagne A, Klitgaard H, Wolff C. Brivaracetam does not modulate the major ionic conductances in neurons. Epilepsia. 2015;56(Suppl 1):192–193.
   Google Scholar
• Daniels V, Wood M, Leclercq K, Kaminski RM, Gillard M. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. Br J Pharmacol. 2013;169(5):1091–1101. doi:10.1111/bph.1219223530581
   PubMed Web of Science ®Google Scholar
• Niespodziany I, André VM, Leclère N, Hanon E, Ghisdal P, Wolff C. Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons. CNS Neurosci Ther. 2015;21(3):241–251. doi:10.1111/cns.1234725444522
   PubMed Web of Science ®Google Scholar
• Niespodziany I, Rigo JM, Moonen G, Matagne A, Klitgaard H, Wolff C. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons. Epilepsia. 2017;58(11):e157–e161. doi:10.1111/epi.1389028850675
   PubMed Web of Science ®Google Scholar
• Detrait ER, Leclercq K, Matagne A, Klitgaard H. Protective activity of brivaracetam in the 6 Hz model of partial epilepsy: comparison with levetiracetam older antiepileptic drugs. Annual Meeting of American Epilepsy Society; 12 6; 2008; Seattle, Washington.
   Google Scholar
• Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and antiepileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154:1662–1671. doi:10.1038/bjp.2008.19818500360
   PubMed Web of Science ®Google Scholar
• Leclercq K, Kaminski R. Anticonvulsant effects of brivaracetam in the 6 Hz fully-kindled mice. International Epilepsy Congress; 9 6; 2015; Istanbul, Turkey.
   Google Scholar
• Klitgaard H, Matagne A. Mechanisms of action of levetiracetam and newer SV2A ligands In: Shorvon S, Pedley TA, editors. The Epilepsies 3. Philadelphia: Butterworth Heineman Elsevier; 2008:28–38.
   Google Scholar
• Klitgaard H, Matagne A, Schachter S, et al. Animal and translational models of the epilepsies In: McArthur RA, Borsini F, editors. Animal and Translational Models for CNS Drug Discovery. New York: Academic Press; 2008:311–335.
   Google Scholar
• Tai KK, Truong DD. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J. Neural Transm (Vienna). 2007;114(12):1547–1551. doi:10.1007/s00702-007-0788-3
   PubMed Web of Science ®Google Scholar
• Wasterlain C, Suchomelova L, Matagne A, et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia. 2005;46:219–220.
   Web of Science ®Google Scholar
• Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia. 2011;52(2):264–272. doi:10.1111/j.1528-1167.2010.02746.x20887370
   PubMed Web of Science ®Google Scholar
• Kruithof AC, Watanabe S, Peeters PA, et al. Pharmacological interactions between brivaracetam and ethanol in healthy males. J Psychopharmacol. 2017;31(7):915–926. doi:10.1177/026988111666532627649776
   PubMed Web of Science ®Google Scholar
• French JA, Costantini C, Brodsky A, von Rosenstiel P; N01193 Study Group. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519–525. doi:10.1212/WNL.0b013e3181ec7f7f20592253
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89–97. doi:10.1111/j.1528-1167.2012.03598.x
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56. doi:10.1111/epi.1243224256083
   PubMed Web of Science ®Google Scholar
• Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66. doi:10.1111/epi.1243324446953
   PubMed Web of Science ®Google Scholar
• Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38–46. doi:10.1111/epi.1239124116853
   PubMed Web of Science ®Google Scholar
• Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–1898. doi:10.1111/epi.1321226471380
   PubMed Web of Science ®Google Scholar
• Kälviäinen R, Genton P, Andermann E, et al. Brivaracetam in unverricht-lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016;57(2):210–221. doi:10.1111/epi.1327526666500
   PubMed Web of Science ®Google Scholar
• Arnold S, Badalamenti V, Diaz A, et al. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control, phase III studies. Epilepsy Res. 2018;141:73–82. doi:10.1016/j.eplepsyres.2018.02.00529486396
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Whitesides J, Schiemann J, D'Souza J, Johnson ME. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016;127:114–118.27589414
   PubMed Web of Science ®Google Scholar
• Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy Behav. 2018;80:129–134. doi:10.1016/j.yebeh.2017.12.02429414542
   PubMed Web of Science ®Google Scholar
• Asadi-Pooya AA, Sperling MR, Chung S, et al. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: a post-hoc study. Epilepsy Res. 2017;131:70–75. doi:10.1016/j.eplepsyres.2017.02.00728279891
   PubMed Web of Science ®Google Scholar
• Brigo F, Bragazzi NL, Nardone R, Trinka E. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs. Seizure. 2016;42:29–37. doi:10.1016/j.seizure.2016.08.00727710868
   PubMed Web of Science ®Google Scholar
• Charokopou M, Harvey R, Srivastava K, Brandt C, Borghs S. Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis. Curr Med Res Opin. 2019;25:1–10.
   Google Scholar
• Zhu LN, Chen D, Chen T, Xu D, Chen SH, Liu L. The adverse event profile of brivaracetam: a meta-analysis of randomized controlled trials. Seizure. 2017;45:7–16. doi:10.1016/j.seizure.2016.11.00827898363
   PubMed Web of Science ®Google Scholar
• Witt JA, Elger CE, Helmstaedter C. Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting-preliminary data. Seizure. 2018;62:49–54. doi:10.1016/j.seizure.2018.09.01630278348
   PubMed Web of Science ®Google Scholar
• Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D’Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(Pt A):165–168. doi:10.1016/j.yebeh.2015.09.00526432008
   PubMed Web of Science ®Google Scholar
• Toledo M, Abraira L, Mazuela G, Quintana M, Cazorla S, Santamarina E. Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study. Seizure. 2019;69:198–203. doi:10.1016/j.seizure.2019.04.02131079028
   PubMed Web of Science ®Google Scholar
• Theochari E, Cock H, Lozsadi D, Galtrey C, Arevalo J, Mula M. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. Epilepsy Behav. 2019;90:129–131. doi:10.1016/j.yebeh.2018.11.03230530134
   PubMed Web of Science ®Google Scholar
• Sanon NT, Gagné J, Wolf DC, et al. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model. Epilepsy Behav. 2018;79:117–125. doi:10.1016/j.yebeh.2017.11.01929287214
   PubMed Web of Science ®Google Scholar
• Steinig I, von Podewils F, Möddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. Epilepsia. 2017;58(7):1208–1216. doi:10.1111/epi.1376828480518
   PubMed Web of Science ®Google Scholar
• Villanueva V, López-González FJ, Mauri JA, et al. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139(4):360–368. doi:10.1111/ane.1305930506559
   PubMed Web of Science ®Google Scholar
• Schubert-Bast S, Willems LM, Kurlemann G, et al. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89–93. doi:10.1016/j.yebeh.2018.10.01830390435
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Steinig I, Willems LM, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav. 2017;70(Pt A):177–181. doi:10.1016/j.yebeh.2017.03.02828427029
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59(8):1549–1556. doi:10.1111/epi.1447629943451
   PubMed Web of Science ®Google Scholar
• Kalss G, Rohracher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia. 2018;59(Suppl 2):228–233. doi:10.1111/epi.1448630043427
   PubMed Web of Science ®Google Scholar
• Aicua-Rapun I, André P, Rossetti AO, Decosterd LA, Buclin T, Novy J. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res. 2019;149:88–91. doi:10.1016/j.eplepsyres.2018.12.00130530123
   PubMed Web of Science ®Google Scholar
• Santamarina E, Parejo Carbonell B, Sala J, et al. Use of intravenous brivaracetam in status epilepticus: A multicenter registry. Epilepsia. 2019;60(8):1593–1601. doi:10.1111/epi.1609431260101
   PubMed Web of Science ®Google Scholar
• Brigo F, Lattanzi S, Nardone R, Trinka E. Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs. 2019;33(8):771–781. doi:10.1007/s40263-019-00652-031342405
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69(10):1027–1034. doi:10.1212/01.wnl.0000271385.85302.5517785672
   PubMed Web of Science ®Google Scholar
• Goldstein ED, Feyissa AM. Brain tumor related-epilepsy. Neurol Neurochir Pol. 2018;52(4):436–447. doi:10.1016/j.pjnns.2018.06.00130122210
   PubMed Web of Science ®Google Scholar
• Bedetti C, Romoli M, Maschio M, et al. Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicenter prospective observational study. Eur J Neurol. 2017;24(10):1283–1289. doi:10.1111/ene.1337528796376
   PubMed Web of Science ®Google Scholar
• Feyissa AM. Antiepileptic drug-related neuropsychiatric adverse events in brain tumor-related epilepsy: levetiracetam front and center. Eur J Neurol. 2017;24(12):1435–1436. doi:10.1111/ene.1339928963765
   PubMed Web of Science ®Google Scholar
• Rizzo A, Donzelli S, Girgenti V, et al. In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res. 2017;36(1):76. doi:10.1186/s13046-017-0546-928587680
   PubMed Web of Science ®Google Scholar
• Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in alzheimer’s disease: causes and clinical relevance. Lancet Neurol. 2017;16(4):311–322. doi:10.1016/S1474-4422(17)30044-328327340
   PubMed Web of Science ®Google Scholar
• Nygaard HB, Kaufman AC, Sekine-Konno T, et al. Brivaracetam, but not ethosuximide, reverses memory impairments in an alzheimer’s disease mouse model. Alzheimers Res Ther. 2015;7(1):25. doi:10.1186/s13195-015-0110-925945128
   PubMed Web of Science ®Google Scholar
• Lamberty Y, Margineanu DG, Klitgaard H. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy Behav. 2000;1(5):333–342. doi:10.1006/ebeh.2000.009812609164
   PubMed Web of Science ®Google Scholar
• Magalhães JC, Gongora M, Vicente R, et al. The influence of levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach. Clin Psychopharmacol Neurosci. 2015;13(1):83–93. doi:10.9758/cpn.2015.13.1.8325912541
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav. 2008;12:305–310. doi:10.1016/j.yebeh.2007.10.00318024209
   PubMed Web of Science ®Google Scholar
• Willems LM, Bertsche A, Bösebeck F, et al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol. 2018;9:569. doi:10.3389/fneur.2018.0056930083127
   PubMed Web of Science ®Google Scholar